AI in Pharmacovigilance Market to Reach USD 1.9 Billion by 2035 | Size, Share, Trends & Forecast (2025–2035)
Market Overview
According to Market
Genics, the AI
in Pharmacovigilance Market is estimated to be valued at USD 0.4 Billion
in 2025 and is projected to reach USD 1.9 Billion by 2035,
registering a CAGR of 17.1% during the forecast period.
The market is
experiencing rapid growth due to the increasing demand for automated drug
safety monitoring, rising volumes of adverse event reports, and g rowing
adoption of artificial intelligence across the pharmaceutical industry.
AI-powered pharmacovigilance solutions leverage machine learning (ML),
natural language processing (NLP), robotic process automation (RPA), predictive
analytics, and cloud computing to streamline adverse event detection, case
processing, signal management, and regulatory reporting.
The increasing
complexity of global drug development, stringent regulatory requirements,
expanding real-world evidence (RWE) initiatives, and the growing use of
electronic health records (EHRs) are accelerating the adoption of AI-based
pharmacovigilance platforms. These technologies enable pharmaceutical companies
and healthcare organizations to improve patient safety, enhance compliance,
reduce operational costs, and accelerate decision-making.
To obtain a free
sample research report - https://marketgenics.co/download-report-sample/ai-in-pharmacovigilance-market-59587?utm_source=Free&utm_medium=ruchika
Market Growth Drivers
Increasing Volume of Adverse Drug Event Reports
The growing number
of adverse drug reaction (ADR) reports generated from healthcare providers,
patients, clinical trials, and post-marketing surveillance is driving the need
for AI-powered pharmacovigilance solutions.
Rising Adoption of Artificial Intelligence in Drug Safety
AI technologies
automate case intake, medical coding, literature screening, duplicate
detection, and signal identification, significantly improving operational
efficiency and reducing manual workloads.
Stringent Regulatory Compliance Requirements
Global regulatory
agencies continue to strengthen pharmacovigilance guidelines, encouraging
pharmaceutical companies to adopt AI-enabled systems for accurate safety
reporting and compliance.
Growth in Real-World Evidence and Real-World Data
The increasing use
of electronic health records, insurance claims, wearable devices, and patient
registries is creating vast datasets that AI can analyze to identify emerging
safety signals.
Expansion of Biopharmaceutical Research
Growing investments
in biologics, biosimilars, gene therapies, vaccines, and personalized medicine
are increasing the complexity of drug safety monitoring throughout the product
lifecycle.
Cloud-Based Pharmacovigilance Platforms
Cloud deployment
enables scalable data processing, secure collaboration, and real-time
monitoring across global pharmacovigilance operations.
Key Players
- Oracle Health
- IQVIA
- ArisGlobal
- Veeva Systems
- Cognizant
- Accenture
- IBM Corporation
- Microsoft Corporation
- SAS Institute
- Parexel
- ICON plc
- Labcorp Drug Development
- TCS (Tata Consultancy Services)
- Capgemini
- Wipro Limited
Regional Insights
North America
North America
dominates the AI in Pharmacovigilance Market due to its advanced pharmaceutical
industry, robust regulatory environment, high adoption of AI technologies, and
significant investments in drug safety and clinical research.
Europe
Europe continues to
hold a substantial market share driven by increasing pharmacovigilance
regulations, expanding pharmaceutical research, and widespread adoption of
digital healthcare technologies.
Asia-Pacific
Asia-Pacific is
expected to register the fastest CAGR during the forecast period due to growing
pharmaceutical manufacturing, increasing clinical research outsourcing,
expanding healthcare digitalization, and rising AI adoption.
Latin America
Growing
pharmaceutical production, improving healthcare infrastructure, and increasing
regulatory focus on drug safety are supporting market expansion across Brazil
and Mexico.
Middle East & Africa
The region is
gradually adopting AI-powered pharmacovigilance solutions as governments
strengthen healthcare systems, pharmaceutical regulations, and digital health
initiatives.
Future Outlook
The AI in
Pharmacovigilance Market is expected to witness significant innovation as
pharmaceutical companies increasingly adopt intelligent automation for drug
safety management.
Key trends shaping
the future include:
- AI-powered adverse event detection and
case processing
- Natural language processing for
literature and social media monitoring
- Predictive safety signal detection using
machine learning
- Integration of real-world evidence (RWE)
and real-world data (RWD)
- Cloud-based pharmacovigilance platforms
- Robotic Process Automation (RPA) for
regulatory workflows
- AI-assisted benefit-risk assessment
- Automated regulatory submissions and
compliance reporting
- Generative AI for pharmacovigilance
documentation
- End-to-end digital drug safety
ecosystems
As pharmaceutical
companies continue to prioritize patient safety, regulatory compliance, and
operational efficiency, AI-driven pharmacovigilance platforms will become
increasingly essential throughout the drug development lifecycle. Continuous
advancements in AI, automation, and cloud computing are expected to reduce case
processing times, improve signal detection accuracy, and enhance global
pharmacovigilance operations.
Related Reports:
Comments
Post a Comment